Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a U.S.-based clinical-stage pharmaceutical company focused on developing dermatology products, including XYNGARI™ and DMT410, with a recent shift toward OTC acne kits and other skin-condition applications. The company has no approved products or product revenue to date and is still building the regulatory, manufacturing, and commercial infrastructure needed to launch products.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueIncludes XYNGARI™ and related clinical programs being developed for acne and other skin conditions.
Includes planned over-the-counter acne kits intended for consumer retail and digital channels.
Includes DMT410 and related applications for aesthetic and medical dermatology uses.
Includes technology platform development, clinical collaborations, and licensing-related work.
Customers
Dermata’s direct customers are not yet commercial end users, because the company has no approved products and no product sales. Its future buyers are expected to include consumers seeking OTC acne treatments, clinics and professionals using dermatology products, and potentially retail or e-commerce channel partners that distribute the products.
Consumers who would buy OTC acne kits for convenient self-treatment through retail or digital channels.
Clinics and practitioners that may use or recommend topical dermatology products in professional settings.
Distributors, retailers, and online channels that would carry and market the company’s OTC products.
Patients enrolled in studies for acne, hyperhidrosis, and other skin-condition programs.
Partners such as Revance that support clinical development, validation, or future commercialization.
Strategy
Dermata is pivoting from an Rx development model toward OTC pathways, with a focus on acne kits and related dermatology products that may be faster and cheaper to commercialize. Near term, the company is trying to preserve cash, complete development work, and secure additional capital or collaborations to fund clinical, regulatory, and launch activities.
OTC pathways may reduce regulatory complexity and manufacturing cost versus Rx development.
The company has recurring losses and a going-concern risk, so funding is required to continue operations.
Successful trials and regulatory pathway selection are needed to support product launch and value creation.
Commercialization depends on compliant manufacturing and reliable third-party supply chains.
Geography
Dermata is headquartered in the United States and its disclosed clinical activity is concentrated there, including a Phase 2a hyperhidrosis study enrolling patients across U.S. sites. The company also references international competition and global supply-chain exposure, but its current operating footprint appears primarily U.S.-based.
Risks
Dermata is a pre-revenue biotech with substantial financing risk, regulatory execution risk, and dependence on third-party manufacturing and distribution. Its shift to OTC pathways adds uncertainty around approvals, labeling, reformulation, and counterfeit exposure, while its small scale makes it vulnerable to cash burn and supply-chain disruptions.
- Insufficient financing and going-concern riskImpact: Critical
The company has recurring losses, limited cash runway, and needs more capital to fund development and launch plans.
Exposure - OTC regulatory pathway uncertaintyImpact: HighLikelihood: High
Moving from Rx to OTC monograph or OTC NDA pathways can require reformulation, relabeling, or additional studies.
Exposure: Product launch timing and cost
- Third-party manufacturing and supply-chain dependenceImpact: HighLikelihood: Medium
The company relies on external manufacturers and logistics providers for clinical and commercial supply.
Exposure: Product availability and margins
- Counterfeit and unauthorized productsImpact: MediumLikelihood: Medium
OTC products can be copied or sold through unauthorized channels, harming consumers and brand trust.
Exposure: Brand reputation and sales
- Competition from private label and established brandsImpact: MediumLikelihood: Medium
OTC dermatology products compete against heavily marketed brands and lower-priced retailer labels.
Exposure: Market share and pricing
Accounting
Judgemental itemsClinical and manufacturing costs are recognized as incurred, and estimates can shift as vendor invoices and trial milestones change.
Impact: Can materially change quarterly operating loss
Payments made before services are received are capitalized and then expensed later, affecting timing of expense recognition.
Impact: Creates quarter-to-quarter volatility in R&D
As a development-stage company, equity awards can be a meaningful non-cash expense in SG&A and R&D.
Impact: Affects reported losses and dilution analysis
Management’s cash runway estimate and funding assumptions are central to the financial statement narrative.
Impact: Signals financing dependence and survival risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Turn Therapeutics Inc.
TTRX · Pharmaceutical Preparations
Damora Therapeutics, Inc.
DMRA · Pharmaceutical Preparations
Azitra, Inc.
AZTR · Pharmaceutical Preparations
Protara Therapeutics, Inc.
TARA · Biological Products, (No Diagnostic Substances)
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Last updated: 24/09/2026